Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Soochow UniversityActive in the last 2 years

Kai Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-4594-1053; OpenAlex author ID A5102029891. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
32
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 2 papers · 2016: 3 papers · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 2 papers

Papers 12

  1. Development and validation of an MBD3/UHRF1 methylation-regulator-based prognostic model for pancreatic cancer survival. Last author DOI 10.21037/tcr-24-1887↗
  2. Multi-omics analyses inform mechanisms of immunotherapy response in pancreatic cancer. Co-author DOI 10.3389/fimmu.2025.1673098↗
  3. Prognostic evaluation of pancreatic cancer based on the model of chemo-radiotherapy resistance-related genes. Last author DOI 10.21037/jgo-23-308↗
  4. Author Correction: Cantharidin represses invasion of pancreatic cancer cells through accelerated degradation of MMP2 mRNA. Co-author DOI 10.1038/s41598-021-84394-4↗
  5. Inflammation Promotes Progression of Pancreatic Cancer Through WNT/β-Catenin Pathway-Dependent Manner. Co-author DOI 10.1097/mpa.0000000000001386↗
  6. The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer. Co-author DOI 10.1038/s41389-018-0102-2↗
  7. Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-κB pathway dependent repression of PP2Ac. Co-author DOI 10.1080/15384101.2015.1127468↗
  8. FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis. Co-author DOI 10.18632/oncotarget.9975↗
  9. B7-H3 and B7-H4 are independent predictors of a poor prognosis in patients with pancreatic cancer. Co-author DOI 10.3892/ol.2016.4128↗
  10. Effect of Diabetes Mellitus on Survival in Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis. Co-author DOI 10.1038/srep17102↗
  11. FH535 inhibited metastasis and growth of pancreatic cancer cells. Co-author DOI 10.2147/ott.s82718↗
  12. Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathwa… Co-author DOI 10.1016/j.ejca.2011.08.014↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Min Tao · 8 shared papers, 2011–2021 · strength 0.51
  2. Mengyao Wu · 4 shared papers, 2016–2025 · strength 0.48
  3. Mengdan Xu · 3 shared papers, 2018–2025 · strength 0.40
  4. Qiaoming Zhi · 5 shared papers, 2016–2021 · strength 0.39
  5. Xue Cheng · 1 shared paper, 2025 · strength 0.37
  6. Chunbin Wang · 1 shared paper, 2025 · strength 0.37
  7. Meng Shen · 5 shared papers, 2015–2021 · strength 0.36
  8. Jinming Cao · 1 shared paper, 2025 · strength 0.25
  9. Dapeng Li · 1 shared paper, 2025 · strength 0.25
  10. Yecheng Li · 1 shared paper, 2025 · strength 0.25
  11. Ge Li · 1 shared paper, 2025 · strength 0.25
  12. Wěi Li · 1 shared paper, 2023 · strength 0.20
  13. Hui‐Chuan Sun · 1 shared paper, 2023 · strength 0.20
  14. Mengyao Wu · 3 shared papers, 2015–2019 · strength 0.20
  15. Daoming Li · 3 shared papers, 2011–2021 · strength 0.20
  16. Wei Li · 2 shared papers, 2016–2021 · strength 0.18
  17. Wei Li · 3 shared papers, 2015–2018 · strength 0.17
  18. Weiming Duan · 3 shared papers, 2011–2016 · strength 0.12
  19. Yixiang Mao · 2 shared papers, 2015–2016 · strength 0.12
  20. Lian Lian · 2 shared papers, 2015–2016 · strength 0.10
  21. Wei Li · 1 shared paper, 2019 · strength 0.08
  22. Rui Ren · 1 shared paper, 2019 · strength 0.08
  23. Wei Li · 1 shared paper, 2016 · strength 0.06
  24. Hong Xu · 1 shared paper, 2016 · strength 0.06
  25. Hongwei Tang · 1 shared paper, 2015 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.